Anbio Biotechnology (NASDAQ:NNNN - Get Free Report)'s stock price dropped 5.5% on Wednesday . The stock traded as low as $27.00 and last traded at $27.25. Approximately 18,667 shares were traded during trading, a decline of 64% from the average daily volume of 52,552 shares. The stock had previously closed at $28.84.
Analyst Upgrades and Downgrades
Separately, Weiss Ratings cut Anbio Biotechnology from a "hold (c-)" rating to a "sell (d+)" rating in a report on Wednesday, April 1st. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock has an average rating of "Sell".
Get Our Latest Report on NNNN
Anbio Biotechnology Trading Down 3.8%
The company has a 50-day moving average of $24.38.
Anbio Biotechnology (NASDAQ:NNNN - Get Free Report) last announced its earnings results on Tuesday, April 7th. The company reported $0.03 earnings per share (EPS) for the quarter.
Anbio Biotechnology Company Profile
(
Get Free Report)
Anbio Biotechnology is dedicated to the advancement of medical technology and the provision of in vitro diagnostics (IVD) products. Our unwavering commitment lies in transforming the diagnostics landscape on a global scale, fostering a paradigm shift towards personalized and decentralized diagnostic solutions. By doing so, we aim to significantly enhance patient prognosis and contribute to the betterment of healthcare worldwide. At Anbio Biotechnology, our extensive portfolio comprises an array of IVD products designed to cater to diverse diagnostic needs.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Anbio Biotechnology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Anbio Biotechnology wasn't on the list.
While Anbio Biotechnology currently has a Sell rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead.
This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
